Taking oral semaglutide may reduce heart-related hospitalizations and deaths among those with a history of heart failure and type 2 diabetes, a new analysis suggests.
Data from a trial funded by Novo Nordisk – which produces the…
Continue Reading
News Source: www.sciencealert.com

Leave a Reply